Category Archives: Solos

Solos Endoscopy, Inc.

Business Description
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos’ sales team can help make the right buying decisions for the hospital, surgery center, or physician office.

Solos Endoscopy’s MammoView(R) System Offers Women Early Breast Cancer Detection

Solos Endoscopy, Inc. (OTC PINK: SNDY) is pleased to announce that the Companys MammoView(R) Breast Endoscopy System can aid in giving women the best prognosis for recovery by detecting breast cancer at an earlier stage than conventional methods (http://www.solosendoscopy.com/ductoscope-sell-sheet-final.pdf).
Physicians using the MammoView(R) Breast Endoscopy System can detect cancerous cells at .25mm compared to 1cm using the average conventional screening methods. Micro endoscopic detection allows physicians to clearly see the boundary between healthy and abnormal tissue. As a result, the MammoView(R) can improve the chances that breast cancer be detected at an early stage and treated successfully.
Solos Endoscopy believes that all women, not just the rich and famous, need to benefit from early detection of breast cancer. Women from all walks of life need to know their options for detecting and preventing breast cancer, short of a mastectomy. Breast cancer is the most common cancer among women in the world. Of the five million women expected to die from breast cancer in the next decade, 70 percent will live in under developed countries.
Too many women discover they have been diagnosed with “breast cancer” at a point when their options for treatment are limited. The importance of early detection to treatment is well-recognized for reducing women’s chances of dying from breast cancer. Breast health awareness, is a given in this country, however, many insurance companies do not normally cover mammary ductoscopy procedures for early detection.
It is well documented that early detection is crucial in the fight against breast cancer. The MammoView(R) System is designed to significantly reduce the detection time and I believe it is an essential tool for early breast cancer screening and treatment, stated Bob Segersten, President of Solos Endoscopy, Inc.
The Solos MammoView(R) Breast Endoscopy System can help more women detect early signs of disease and thereby seek advice as to multiple treatment options that early detection can offer. Experts at theBreast Health Global Initiative(http://portal.bhgi.org/Pages/Default.aspx) and elsewhere propose tiered guidelines for diagnosis and treatment based on what’s suitable and affordable for a country or community. Solos Endoscopy supports implementing such guidelines now and giving Women more options for the early screening and detection of breast cancer.
The Solos MammoView(R) Breast Endoscopy System employs advanced microendoscopes and optical technology which gives physicians sharp images of the milk ducts where the majority of breast cancer arises. Solos Endoscopy instruments are FDA approved. Upon Solos Endoscopys receipt of its ISO 13485 Certification, the Company will be able to place the CE Mark on its entire MammoView(R) instrument line which will allow the instrument line to be sold globally. Both Solos and Expert Resource believe the ISO 13485 Certification and CE Mark initiative will be completed within the next few months.

Anesthetic Drugs Procurement Research Report Now Available from IBISWorld

Anesthetic drugs have a buyer power score of 2.5 out of 5. The score reflects current negative pricing trends and indicates a moderate level of buyer bargaining power. “Prices for anesthetics have fluctuated over the past three years as a result of rising regulatory compliance costs and generics competition,” says IBISWorld procurement analyst Anna Son. The patent expiration of many blockbuster drugs has increased availability of generic anesthetics, which are typically far less expensive than their brand-name counterparts, thus helping to mitigate price growth over the past three years. Nevertheless, a limited number of suppliers of anesthetics that are in short supply, such as propofol, has kept prices high due to the constrained supply of those drugs.

The cost associated with switching anesthetics suppliers varies depending on the type of supplier. For example, buyers can expect lower switching costs associated with suppliers of commonly used anesthetics, such as ketamine, because of their instant availability and low buying lead time. “This provides buyers with the opportunity to restock their inventory in a relatively short time frame, barring contract negotiations,” says Son. In this case, buyers of anesthetic drugs have greater leverage in negotiating contracts. On the contrary, buyers are more likely to incur higher costs when they switch suppliers of anesthetics that are in short supply, especially when there are only a small number of suppliers of that particular drug. As such, suppliers of rare anesthetics have greater negotiating power over buyers. Some of the major vendors include Abbott Laborato

Solos Endoscopy (SNDY) Surges 80% As Joint Venture Talks With Olea Medical Happen In Cambridge, Massachusetts Ventures Sierra World Equity Review

Solos Endoscopy (SNDY) Surges 80% As Joint Venture Talks With Olea Medical Happen In Cambridge, Massachusetts Ventures Sierra World Equity Review. Big money has been accumulating shares in SNDY as it nears receiving the CE mark approval, epic run coming forecasts accurate Sierra!
More about Sierra: Hi, my name is Sierra and I’m 28 yrs old and I live in beautiful Key West, Florida. When I’m not playing beach volleyball or modelling my passion is blogging and trading stocks. On the weekends I’m normally at Sloppy Joes or The Schooner Wharf Bar enjoying the nightlife, dance be happy, enjoy life and good luck in all your trades! Here are some more of my recent stock forecasts and predictions:
Liquidmetal Technologies (LQMT) Surges 223% As Apple (AAPL) Acquisition Discussions In California Leak Out Ventures Sierra World Equity Review. Watch for an official PR coming forecasts Sierra!
Busy NanoTech Entertainment (NTEK) Continues Execution Of It’s Business Plan, Following The Acquisition Of Clear Memories NTEK Now Poised To Release Announcement On 4K TV Partnership Within the Next 14 Days As The Deal Is Almost Finalized Ventures Sierra World Equity Review.
Accumulation Of Shares Continuing As MyECheck, (MYEC) Share Price Poised To Explode Upwards As eBay Buyout Announcement Coming Down The Pike Predicts Sierra World Equity Review.
Sierra Was Right As Premier Brands (BRND) Soars Another 36% As New Distribution Agreements To Get Announced Following Webinar For Bad Boy Vodka Next Week Ventures Sierra World Equity Review. Share price to continue moving in one direction, UP forecasts Sierra!
Positive News Coming To Shareholders Of ALAS International Holdings (VDSC) As A New Press Release Coming With Info On Dividend Date, No R/S And New Acquisition Ventures Sierra World Equity Review. Hang on as VDSC is going to run hard forecasts Sierra!
Yet Again Sierra Was Correct As Minerco Resources (MINE) Continues It’s “Rise” Up Another 10% Prior To Coming Announcement On Agreement With National Distributor Ventures Sierra World Equity Review.
Accurate Sierra Told You Big News Was Coming As Creative Edge Nutrition (FITX) Rises 17% As The Company Releases Letter To Shareholders & PR’s News Of New Retail Contract. Just the beginning forecasts Sierra, even more big news coming as a huge new joint venture announcement gets prepared predicts Sierra World Equity Equity
As Koma Unwind Success Continues Bebida Beverage Company (BBDA) Talking to Coca-Cola (KO) Ventures Sierra World Equity Review As Now New Partnership (not acquisition) Takes Centerfold Forecasts Sierra.
Sierra Nails It Again As Expert Group (EXPU) Jumps 12% As Ingels Markets Comes Into The Fold, Now Sierra World Equity Review Predicts That EXPU And Winn-Dixie Are Close To Inking A Deal. Watch for big news about Winn-Dixie coming before the end of August ventures accurate Sierra!
Hannover House (HHSE) Share Price To Rise As New PR To Detail Updated Financials And Uplisting Ventures Sierra World Equity Review. Watch for big news within the next 14 days forecasts Sierra!
SK3 Group (SKTO) Share Rise 19% As Management Demonstrates It’s Intentions To Provide Shareholder Value With Ongoing Preparation Of New Positive And Verifiable Press Release Ventures Sierra World Equity Review. Look for a PR to come out prior to July 26th forecasts Sierra!
Greenfield Farms Food (GRAS) To Release Announcement Regarding Reverse Split Ventures Sierra World Equity Review. Watch for the PR coming, bad news for shareholders predicts Sierra!
United Western Bancorp (UWBKQ) Shares Rise 68% As Imminent Press Release Containing Big News Regarding Claims To Be Released Predicts Sierra World Equity Review. Share price to keep rising forecasts accurate Sierra!
North Bay Resources (NBRI) To Start Epic Run As News Coming Out On New Yields From Gold Production From The Ruby Mine Vastly Exceed Prior Forecasts Predicts Sierra World Equity Review. Look for the PR coming within 14 days ventures Sierra!
Following District Court Judge Order Chastising JP Morgan (JPM) And Demanding The Turnover Of Institutional Investors Documents, JPM Now Expediting Settlement Discussions With WMI Holdings (WMIH) Ventures Sierra World Equity Review. Good news coming to shareholders of WMIH as JPM caves forecasts Sierra!
Accurate Sierra Was Correct As NanoTech Entertainment (NTEK) Surges 21% As Partnership With Microsoft (MSFT) To Be Announced Ventures Sierra World Equity Review.
Primco Management (PMCM) Falls 46% On Profit Taking, Sierra World Equity Review Forecasts A Big Bounce As News Regarding Progress Toward Uplisting To The Nasdaq Is Announced In The Next PR On Tuesday Or Wednesday Predicts Sierra!
Sierra Was Right As Minerco Resources (MINE) Soars 42% As Institutional Buying Prior To Announcement On Agreement With National Distributor Predicts Sierra World Equity Review.

Solos Endoscopy Completes Stage 2 of its ISO 13485 Audit with TU

ISO 13485:2003 certification is also a necessary for the company to sell the MammoView[R] product line in Canada. The Company expects the entire process to be concluded by the end of the year, which will allow the Company to market and sell its instruments internationally in 2014. Solos Endoscopy retained Emergo Europe to act as the official Authorized Representative in Europe. Emergo will provide Solos assistance related to communications with authorities and importation of Solos instruments in Europe. Emergo Group will register Solos instruments with the Competent Authorities (Ministry of Health) as required, including the Dutch Ministry of Health. Emergo will act as a liason for Solos Endoscopy between the European Commission and national Competent Authorities. Emergo Europe consultants will assist Solos with a wide variety of regulatory, quality assurance, and distribution. We would like to thank TUV SUD America and Expert Resources for their continued support as we accomplish our goal to market Solos instruments worldwide, stated Robert Segersten, Solos Endoscopy, CEO. The Solos MammoView[R] Breast Endoscopy System employs advanced microendoscopes and optical technology which gives physicians sharp images of the milk ducts where the majority of breast cancer arises. Solos Endoscopy instruments are FDA approved. Upon Solos Endoscopys receipt of its ISO 13485 Certification, the Company will be able to place the CE Mark on its entire MammoView[R] instrument line which will allow the instrument line to be sold globally. About Solos Endoscopy, Inc.: Solos Endoscopy is celebrating its 25th Year of providing quality innovative healthcare instruments to Hospitals across the Country. For more than 25 Years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions.

Solos Endoscopy

Since the start of July the stock of Solos Endoscopy, Inc. (OTCMKTS:SNDY, SNDY message board) has been desperately trying to stay above the $0.002 and delay its fall into triple zeros. That was the case until noon yesterday when the stock exploded and at closing time it had gained more than 80% to comfortably sit at $0.0038. Investors rushed to buy in resulting in 105 million shares being traded, 17 times more than the previous day. The last time the company enjoyed such attention was in April , 2012.
The reason behind the steep climb was a new press article issued by the company. Although it contained no new information it reminded investors how far the company has progressed with its business plan. Their main product is the MammoView(R) Breast Endoscopy System capable of detecting breast cancer at an earlier stage than the traditional methods.
SNDY have been approved by the FDA and have successfully passed the stage 1 audit for compliance with the international quality standard ISO 13485:2003. The stage 2 audit is scheduled for August 16 and if again passed the company will increase its market dramatically. This standard is required both by the Canadian government in order to allow sales of their product and for the CE mark allowing sales in the EU.

The stock may continue climbing for the next month until the results of the audit have been announced. For now lets leave speculations aside and take a look at SNDY’s fundamentals. They finished the quarter ending March 31 with the following results:

$51 thousand cash
$426 thousand total current assets
$173 thousand total liabilities
$100 thousand revenues
$128 thousand net loss

Island Digestive Health Center – West Islip, New York Commencement of Construction

A coalition of five local GI physicians that includes the practice of Island Digestive Disease Consultants, doctors Kourosh Adhami, MD; Neil Lobo, MD; James Kohlroser, DO; Babak  Danesh, MD; and Krishnaiyer Subramani, MD, a solo physician whose practice is located in West Islip, are pleased to announce the commencement of construction of Island Digestive Health Center (IDHC).

The project received Public Health and Health Planning Council approval on August 29,  2013. Projected to open in the first quarter of 2014, construction on the new three-room center, located in West Islip, Suffolk County, New York, is already underway.

“For many years we’ve practiced office-based endoscopy within our professional practices, and now is the perfect time to develop a new state-of-the-art facility,” stated Dr. Danesh, Medical Director of Island Digestive Health Center.

The new space will provide just what the physicians and community needs, a 6,750 square foot endoscopic ambulatory surgery center (EASC) with three procedure rooms.

“We are excited about the anticipated opening of the center in Q1 2014 and our partnership with this coalition of highly talented GI physicians. This center will provide a new level of comfortable and convenient healthcare services to this community,” says Frank Principati, COO of Physicians Endoscopy (PE) and a board member of Island Digestive Health Center.

“We have been very pleased with Physicians Endoscopy’s ability to help organize, coordinate and execute a strategy to bring together our two practices. We initially met with PE in February 2011 and immediately recognized their ability to make this happen for us,” stated Drs. Adhami and Subramani.

This newly renovated space at 471 Montauk Highway will be licensed by the State of New York, certified by Centers for Medicare and Medicaid Services (CMS), accredited by the Accreditation Association for Ambulatory Health Care (AAAHC) and will be a “Center of Excellence” in every aspect of the term. The center is scheduled to open in March 2014.

Staying at the Forefront of a Rapidly Evolving Field: 5 Gastroenterologists Weigh In

Rapid and transformative changes are taking place in the healthcare industry as a whole, and the gasterenterology field is not immune to these changes.
Here five gastroenterologists discuss the challenges facing them and their peers, and talk about how to nonetheless stay at the forefront of the swiftly evolving field.

Question: In this day and age, what is the most challenging aspect of being in the gastroenterology field?

englanderGlenn Englander, MD, Good Samaritan Medical Center, West Palm Beach, Fla., in connection with The Expert Institute: The reality is that increasingly physicians are becoming employees rather than employers. I was a solo practitioner but now I am part of a group. The more administrative things I used to do, now I do less. So now it is hard to have your pulse on things or problems going on the practice.

Also, there are more and more interventions put upon physicians by the government or insurance agencies that wastes our time and impedes our care. We are constantly filling in paperwork and the quality of care I give is measured by whether I dated and timed every page. Rather than letting good physicians be good physicians we now have to defend ourselves.

Q: How do the demands of governmental regulations affect a gastroenterology practice?

Joel Weinstock, MD, Chief of Division of Gastroenterology/Hepatology, Tufts Medical weinstock 2013Center, Boston, in connection with The Expert Institute: The requirements of documentation. That takes a lot of time and the software is not up to the task. So what once took 15 or 20 minutes now takes 25 to 30 minutes. And does it lead to better quality of care? Not in most cases.

Documentation is important and it’s not wrong, but it shouldn’t take up too much of the physician’s time. Another demand is prior approval. When we decide that a patient needs particular medication and the insurance company doesn’t release the medication or pay for the procedure until they approve it, this can affect patient care and adds to cost

Jeffrey Fine, MD, Chief of Gastroenterology, Medical and Surgical Clinic of Irving, Texas: Many demands are put on us from different sources — regulatory agencies and payers, Jeff Fineelectronic medical records, more and more paperwork requiring us to spend more time completing it — and all the while, we’re trying to provide the best, most cost-effective care available to the patients we serve. This is extremely challenging.

Q: What are some ways in which GI physicians can stay at the forefront of the field? How does continuing education tie into that?

Dr. Weinstock: One sure way of doing it is to learn from medical fellows and residents — learn new things and tricks. Continuing education is important for staying at the forefront of the field. Physicians can go to conferences or even listen to recorded lectures in the car. I also get a certain number of journals and I make a discipline of looking through the journals. Also, physicians can take time off to attend a national or regional meeting of a professional society. You have to put time into it.

John Milliken, MD, Northern Michigan Gastroenterology, Traverse City: Academically, we are very fortunate as gastroenterologists because we have very good organizations such as American College of Gastroenterology, which provides very practical national courses. These are both available by actual attendance or through our computer.

Administratively, again, this is mostly through our national organizations and through our local NPO, which has been extremely helpful in keeping us at the forefront of the upcoming changes in medicine, such as the change from the fee-for-service to fee-for-performance.

Dr. Fine: To stay at the forefront of their field, gastroenterologists have to be willing to explore all treatment options, which means being flexible and keeping up-to-date on the latest technology, techniques, research and trends. No matter how much experience or training you have, you have to keep improving and educating yourself, and you have to keep an open mind about the treatment process. This will enable you to provide better, more comprehensive care. It’s also crucial to have a good network to refer patients to, because some conditions require a higher level of specialization.

Why is it important for physicians to develop expertise in various niches of the GI field?

Razvan Arsenescu, MD, PhD, The Ohio State University Wexner Medical Center, ArsenescuColumbus: I think that it is important for physicians to understand the landscape of healthcare. I think that developing expertise in specialized niches within the field of gastroenterology — like bowel disease or GI oncology or training in new and endoscopic approaches.

For many private practices, the main volume for GI practices comes from screening colonoscopies for cancers. But a new procedure, called virtual colonoscopy, now allows radiologists to gather the same information that screening colonoscopies gather. So they may end up doing diagnostic procedures traditionally performed by GI physicians, thereby affecting their practice volume. So being able to learn new procedures and specialize will give them an edge.

Q: What do you think 2014 holds clinically for GI physicians?

Dr. Fine: We’re starting to see a trend in more preventive care. GI physicians are focusing more on treating the patient as a whole, while addressing the underlying reasons for the GI problem. I believe this trend will continue to grow. Research shows that less conventional therapies, such as food elimination, probiotics and nutritional supplements, can be helpful in treating certain conditions, and patients are becoming more receptive to comprehensive treatment. This treatment and maintenance often address the GI problem while enabling healthier living as a whole.

Dr. Arsenescu: There are new biologic treatments for bowel diseases and new antiviral treatments for hepatitis C. We also have new technology that allows us to get the information that biopsies give, and so GI physicians will be able to get that information. The keys to success will be the ability to be flexible and the ability to reinvent oneself every so many years.

Q: What will implementation of the Patient Protection and Affordable Care Act mean for the GI field as the rollout continues?

Dr. Englander: A fair amount of confusion. There will be a lot of gearing up and time spent towards getting data, that includes clinical data, data on patient satisfaction. I would have forgone all the money that we got from the government for implementing electronic health record systems and other systems because we have lost more money implementing these systems than the amount we are getting back.

Dr. Milliken: The new CPT codes that going to effect in October represent a major challenge for all physicians. In addition, with the Affordable Care Act, none of us know how this will affect our practice of medicine as there are so many unknowns. Also, the change from fee-for-service to fee-for-performance — how this will affect physicians is still somewhat unclear.

Morning Buzzers – MTN Group Ltd

Boston, MA — (SBWIRE) — 12/04/2013 — At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: MTN Group Ltd (ADR) (OTCMKTS:MTNOY), URANIUM PARTC CORP (OTCMKTS:URPTF), SOLOS ENDOSCOPY INC (OTCMKTS:SNDY), iquidmetal Technologies Inc (OTCBB:LQMT)

MTN Group Ltd (ADR) (OTCMKTS:MTNOY) decreased -1.13% at the price of $18.39 recently on a traded volume of 16,485.00 shares, in comparison to 61,543.00 shares of average trading volume. So far this year, the stock is down over -13.89%.

The company has a total market capitalization of $34.84 billion. MTN Group Limited (MTN) is a multinational telecommunications company offering mobile communication and related products and services to individuals and businesses on three continents.

Has MTNOY Found The Bottom and Ready To Move Up? Find Out Here

URANIUM PARTC CORP (OTCMKTS:URPTF) plunged -1.94% at the trading price of $5.05 on a traded volume of 5,600.00 shares till now, whereas its average trading volume is 41,860.00 shares. In the last three months, the stock is up 8.84%. The Intra-day range for the stock is $5.05 and $5.11. Uranium Participation Corporation operates as an investment holding company. The company invests its assets substantially in uranium oxide in concentrates (U3O8). U3O8 is primarily used as a fuel for nuclear power plants. Denison Mines, Inc. operates as the manager of the company. Uranium Participation was founded in 2005 and is headquartered in Toronto, Canada.

Has URPTF Found The Bottom And Ready To Gain Momentum? Find Out Here

SOLOS ENDOSCOPY INC (OTCMKTS:SNDY) dropped down -30.00% at the $0.0007 recently. So far in three months, the stock is down -69.57%. The 52-week range for the stock is $0.0007 and $0.0087. Its introductory price for the day was $0.0008, with the overall traded volume of 17.09 million shares. Solos Endoscopy, Inc., a healthcare technology company, develops and markets technology, applications, medical devices, and procedure techniques for the screening, diagnosis, treatment, and management of medical conditions.

Why Should Investors Buy SNDY After the Recent Fall? Just Go Here and Find Out

Liquidmetal Technologies Inc (OTCBB:LQMT) after opening its shares at the price of $0.17, dropped -0.94% , its recent trading price was $0.168 for the day. The stock moved on a traded volume of 828,157.00 shares, in comparison to 2.47 million shares of average trading volume.

The 52-week range for the stock is $0.05 and $0.23. Its introductory price for the day was $0.17. Liquidmetal Technologies, Inc. (Liquidmetal Technologies) materials technology company that develops and commercializes products made from amorphous alloys. The Company designs, develops and sells products and components from bulk amorphous alloys to customers in various industries.

Will LQMT Get Buyers Even After The Recent Rally? Find Out Here

About winstonsmallcap.com
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t be disappointed.

Solos Endoscopy Reports Results From Stage 2 of Its ISO 13485 Audit With TUV SUD America

BOSTON, MA–(Marketwired – Oct 17, 2013) – Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce that the Company has passed its Stage 2 audit with Notified Body and registrar TÜV SÜD for registration to ISO 13485:2003. The Stage 2 audit was conducted August 15 – 16, 2013. TÜV SÜD found no non-conformities to Solos Endoscopy’s Quality Management System requirements in the audit.

Solos Endoscopy is now in the process of drafting Technical Files and associated documents for the MammoView® devices the company intends to sell in Europe. TÜV SÜD will review the Technical Files for Solos Endoscopy’s sterile devices in the MammoView® system. Since the Ductoscope is a Class I device in the European Union, Solos Endoscopy will prepare the required documentation and self certify without the need for Notified Body review.

Once the documentation has been prepared and TÜV SÜD reviews and approves the required documentation for the sterile devices, TÜV SÜD will certify Solos Endoscopy to ISO 13485:2003 and provide certificates for CE Marking for Solos Endoscopy’s sterile MammoView® system devices. CE Marking will allow Solos Endoscopy to sell its endoscopic instruments, including the MammoView® devices to the European Union. The Company expects the entire process to be concluded by the end of the year. Solos Endoscopy plans to market and sell its instruments internationally in 2014.

“Solos Endoscopy is committed to the worldwide distribution of its endoscopic instruments. We believe this dedication will result in increased sales and profits for the Company and its shareholders,” stated Robert Segersten, Solos Endoscopy CEO.

Solos Endoscopy retained Emergo Europe to act as the official Authorized Representative in Europe. Emergo will provide Solos assistance related to communications with authorities and importation of Solos instruments in Europe. Emergo Group will register Solos instruments with the Competent Authorities (Ministry of Health) as required, including the Dutch Ministry of Health. Emergo will act as a liaison for Solos Endoscopy between the European Commission and national Competent Authorities. Emergo Europe consultants will assist Solos with a wide variety of regulatory, quality assurance, and distribution.

The Solos MammoView® Breast Endoscopy System employs advanced microendoscopes and optical technology, which gives physicians sharp images of the milk ducts where the majority of breast cancer arises. This allows physicians to detect breast cancer significantly faster than the traditional mammography. Solos Endoscopy instruments are FDA approved. Upon Solos Endoscopy’s receipt of its ISO 13485 Certification, the Company will be able to place the CE Mark on its entire MammoView® instrument line which will allow the instrument line to be sold globally.

About Solos Endoscopy, Inc.:

Solos Endoscopy is celebrating its 25 thYear of providing quality innovative healthcare instruments to Hospitals across the Country. For more than 25 Years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions.

For more information on TÜV SÜD America visit www.tuvamerica.com. For more information on Emergo Group visit www.emergogroup.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company’s Annual Report filing and other filings with the OTC Markets Group (available atwww.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.